{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:04:17Z","timestamp":1788494657103,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54CA210181"],"award-info":[{"award-number":["U54CA210181"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.pharmthera.2018.06.007","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T01:20:09Z","timestamp":1529457609000},"page":"43-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Chloroquine and nanoparticle drug delivery: A promising combination"],"prefix":"10.1016","volume":"191","author":[{"given":"Joe","family":"Pelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Busatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Aubrey","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Wolfram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2018.06.007_bb0005","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment","volume":"17","author":"Amaravadi","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0010","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1172\/JCI28833","article-title":"Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma","volume":"117","author":"Amaravadi","year":"2007","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/btm2.10003","article-title":"Nanoparticles in the clinic","volume":"1","author":"Anselmo","year":"2016","journal-title":"Bioengineering and Translation Medicine"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors: Myths, reality and possibility","volume":"153","author":"Bae","year":"2011","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0025","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0030","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1158\/1535-7163.MCT-13-0948","article-title":"Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling","volume":"13","author":"Balic","year":"2014","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.gde.2004.12.005","article-title":"Cellular abnormalities of blood vessels as targets in cancer","volume":"15","author":"Baluk","year":"2005","journal-title":"Current Opinion in Genetics & Development"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)\u2014the first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0045","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2017.35.15_suppl.4106","article-title":"A phase Ib\/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts)","volume":"35","author":"Bekaii-Saab","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0050","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1215\/S1152851705000232","article-title":"The role of pericytes in blood-vessel formation and maintenance","volume":"7","author":"Bergers","year":"2005","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2018.01.022","article-title":"Extracellular vesicle therapeutics for liver disease","volume":"273","author":"Borrelli","year":"2018","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood-2006-10-050260","article-title":"Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance","volume":"110","author":"Carew","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0075","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nnano.2012.45","article-title":"Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner","volume":"7","author":"Chauhan","year":"2012","journal-title":"Nature Nanotechnology"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0080","first-page":"220","article-title":"Autophagy is a therapeutic target in anticancer drug resistance","volume":"1806","author":"Chen","year":"2010","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0085","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/stem.1746","article-title":"Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1","volume":"32","author":"Choi","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0090","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-13-2438","article-title":"Molecular pathways: Autophagy in cancer--a matter of timing and context","volume":"21","author":"Cicchini","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ccr.2006.06.001","article-title":"Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis","volume":"10","author":"Degenhardt","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0100","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1158\/1535-7163.MCT-08-1169","article-title":"Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy","volume":"8","author":"Ding","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.tibtech.2009.12.007","article-title":"Frontiers in cancer nanomedicine: Directing mass transport through biological barriers","volume":"28","author":"Ferrari","year":"2010","journal-title":"Trends in Biotechnology"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2217\/17435889.3.2.137","article-title":"Theranostic nanomedicine for cancer","volume":"3","author":"Gao","year":"2008","journal-title":"Nanomedicine"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0115","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.2217\/fon.13.146","article-title":"Liposomal chemotherapeutics","volume":"9","author":"Gentile","year":"2013","journal-title":"Future Oncology"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0120","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0125","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1242\/jcs.02447","article-title":"The apoptosis\/autophagy paradox: Autophagic vacuolization before apoptotic death","volume":"118","author":"Gonzalez-Polo","year":"2005","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0070-2153(10)92009-7","article-title":"Notch signaling in the vasculature","volume":"92","author":"Gridley","year":"2010","journal-title":"Current Topics in Developmental Biology"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0135","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: The phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0140","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nature06868","article-title":"Vascular normalization in Rgs5-deficient tumours promotes immune destruction","volume":"453","author":"Hamzah","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0145","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nature04724","article-title":"Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice","volume":"441","author":"Hara","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0150","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1248\/bpb.b13-00059","article-title":"The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors","volume":"36","author":"Hatakeyama","year":"2013","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0155","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00436-006-0313-x","article-title":"Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors","volume":"100","author":"Hempelmann","year":"2007","journal-title":"Parasitology Research"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0160","doi-asserted-by":"crossref","first-page":"10980","DOI":"10.1073\/pnas.1106634108","article-title":"Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform","volume":"108","author":"Hu","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0165","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0170","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.addr.2012.09.011","article-title":"Delivery of molecular and cellular medicine to solid tumors","volume":"64","author":"Jain","year":"2012","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0175","doi-asserted-by":"crossref","first-page":"8689","DOI":"10.1021\/acsnano.5b02028","article-title":"Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles","volume":"9","author":"Jiang","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0180","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4132\/jptm.2015.06.01","article-title":"Cancers with higher density of tumor-associated macrophages were associated with poor survival rates","volume":"49","author":"Jung","year":"2015","journal-title":"Journal of Pathology and Translatrion Medicine"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.cdd.4402030","article-title":"DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells","volume":"14","author":"Katayama","year":"2007","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0190","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/17425247.2017.1243527","article-title":"Strategies for improving drug delivery: Nanocarriers and microenvironmental priming","volume":"14","author":"Khalid","year":"2017","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0195","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1038\/onc.2015.511","article-title":"Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells","volume":"35","author":"King","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0200","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.semcdb.2010.03.002","article-title":"Physiological role of autophagy as an intracellular recycling system: With an emphasis on nutrient metabolism","volume":"21","author":"Kuma","year":"2010","journal-title":"Seminars in Cell & Developmental Biology"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0205","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature09782","article-title":"Autophagy in immunity and inflammation","volume":"469","author":"Levine","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0210","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/2159-8290.CD-14-0049","article-title":"Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors","volume":"4","author":"Levy","year":"2014","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0215","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ccr.2014.06.025","article-title":"Tumor vessel normalization by chloroquine independent of autophagy","volume":"26","author":"Maes","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0220","first-page":"9","article-title":"Inhibition of autophagy with bafilomycin and chloroquine decreases mitochondrial quality and bioenergetic function in primary neurons","volume":"11","author":"Matthew Redmann","year":"2017","journal-title":"Redox Biology"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0225","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4161\/auto.8.2.18554","article-title":"Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy","volume":"8","author":"Maycotte","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0230","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","article-title":"Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization","volume":"136","author":"Mazzone","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0235","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/adhm.201500910","article-title":"A micro\/Nano composite for combination treatment of melanoma lung metastasis","volume":"5","author":"Mi","year":"2016","journal-title":"Advanced Healthcare Materials"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0240","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.phrs.2016.08.024","article-title":"Enzyme-responsive multistage vector for drug delivery to tumor tissue","volume":"113","author":"Mi","year":"2016","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0245","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1038\/ncomms9692","article-title":"Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug","volume":"6","author":"Miller","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0250","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.devcel.2015.03.002","article-title":"CALM regulates clathrin-coated vesicle size and maturation by directly sensing and driving membrane curvature","volume":"33","author":"Miller","year":"2015","journal-title":"Developmental Cell"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0255","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nantod.2017.03.001","article-title":"Complement activation turnover on surfaces of nanoparticles","volume":"15","author":"Moghimi","year":"2017","journal-title":"Nano Today"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0260","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1182\/blood.V124.21.5775.5775","article-title":"A phase II trial of chloroquine in combination with bortezomib and cyclophosphamide in patients with relapsed and refractory multiple myeloma","volume":"124","author":"Montanari","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0265","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bjc.6604929","article-title":"Why are tumour blood vessels abnormal and why is it important to know?","volume":"100","author":"Nagy","year":"2009","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0270","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-0030-1253454","article-title":"Heterogeneity of the tumor vasculature","volume":"36","author":"Nagy","year":"2010","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0275","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2174\/138945010791591395","article-title":"Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy","volume":"11","author":"Niu","year":"2010","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: From mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0285","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1016\/j.biomaterials.2014.04.088","article-title":"Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes","volume":"35","author":"Paolino","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0290","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nnano.2012.212","article-title":"Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions","volume":"8","author":"Parodi","year":"2013","journal-title":"Nature Nanotechnology"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0295","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0005-2736(94)90004-3","article-title":"Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles","volume":"1195","author":"Parr","year":"1994","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0300","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2014.12.008","article-title":"Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy","volume":"199","author":"Pasut","year":"2015","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0305","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1172\/JCI20039","article-title":"Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene","volume":"112","author":"Qu","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0310","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1229568","article-title":"Minimal \"self\" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles","volume":"339","author":"Rodriguez","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0315","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1634\/theoncologist.10-3-205","article-title":"Pegylated liposomal doxorubicin: Optimizing the dosing schedule in ovarian cancer","volume":"10","author":"Rose","year":"2005","journal-title":"The Oncologist"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0320","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","article-title":"Endocytosis of nanomedicines","volume":"145","author":"Sahay","year":"2010","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0325","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.colsurfb.2017.07.014","article-title":"Contribution of Kupffer cells to liposome accumulation in the liver","volume":"158","author":"Samuelsson","year":"2017","journal-title":"Colloids and Surfaces B: Biointerfaces"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0330","article-title":"Porous silicon microparticles for delivery of siRNA therapeutics","volume":"52075","author":"Shen","year":"2015","journal-title":"Journal of Visualized Experiments"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0335","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.2147\/IJN.S132780","article-title":"High drug-loading nanomedicines: Progress, current status, and prospects","volume":"12","author":"Shen","year":"2017","journal-title":"International Journal of Nanomedicine"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0340","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1158\/0008-5472.CAN-15-1576","article-title":"Redirecting transport of nanoparticle albumin-bound paclitaxel to macrophages enhances therapeutic efficacy against liver metastases","volume":"76","author":"Tanei","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0345","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2013-05-500629","article-title":"Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells","volume":"122","author":"Torgersen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0350","author":"U.S. National Library of Medicine"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0355","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1039\/C6TB01978A","article-title":"Post-nano strategies for drug delivery: Multistage porous silicon microvectors","volume":"5","author":"Venuta","year":"2017","journal-title":"Journal of Materials Chemistry B"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0360","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1039\/C1CS15233E","article-title":"Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment","volume":"41","author":"Walkey","year":"2012","journal-title":"Chemical Society Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0365","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1021\/jm9018383","article-title":"Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: Interaction with DNA","volume":"53","author":"Wenzel","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0370","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc3262","article-title":"Deconvoluting the context-dependent role for autophagy in cancer","volume":"12","author":"White","year":"2012","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0375","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1158\/1078-0432.CCR-07-5023","article-title":"The double-edged sword of autophagy modulation in cancer","volume":"15","author":"White","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0380","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nature Reviews Materials"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0385","doi-asserted-by":"crossref","first-page":"13738","DOI":"10.1038\/s41598-017-14221-2","article-title":"A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery","volume":"7","author":"Wolfram","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0390","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jconrel.2015.08.010","article-title":"Multistage vector (MSV) therapeutics","volume":"219","author":"Wolfram","year":"2015","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0395","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.colsurfb.2013.10.009","article-title":"Shrinkage of pegylated and non-pegylated liposomes in serum","volume":"114C","author":"Wolfram","year":"2014","journal-title":"Colloids and Surfaces B: Biointerfaces"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0400","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.colsurfb.2014.02.035","article-title":"The nano-plasma interface: Implications of the protein corona","volume":"124","author":"Wolfram","year":"2014","journal-title":"Colloids and Surfaces B: Biointerfaces"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0405","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2174\/1389450115666140804124808","article-title":"Safety of nanoparticles in medicine","volume":"16","author":"Wolfram","year":"2015","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0410","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: Emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology"},{"key":"10.1016\/j.pharmthera.2018.06.007_bb0415","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"Journal of Controlled Release"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T14:21:26Z","timestamp":1571494886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725818301098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":82,"alternative-id":["S0163725818301098"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.06.007","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chloroquine and nanoparticle drug delivery: A promising combination","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}